Erythropoietin and cerebral ischemic injury.docVIP

 PAGE \* MERGEFORMAT 14 Erythropoietin and cerebral ischemic injury [Keywords:] erythropoietin cerebral ischemic injury EPO (erythropoietin, EPO) is produced by the kidney and liver of a fetal red blood cells can promote the formation of cytokines, which through a combination of specific cell surface receptors play a role. In the past that the role of EPO-specific and specific to in hematopoietic cells, but recognized that EPO also has effects on other cells. functional EPO receptors not only in the hematopoietic system, but also present in various non-hematopoietic systems, including central nervous system (central nervous system, CNS.EPO as a cell factor superfamily member, both in vivo and in vitro showed significant neuroprotective function [1]. This paper reviews the EPO in terms of cerebral ischemia and the mechanism of brain protection. 1 EPO’s biological characteristics EPO is the first discovered and clinical application of hematopoietic growth factors. Back in 1906, Carnot and other rabbits found in the peripheral blood after blood loss to produce a role in the hematopoietic system may be to accelerate erythropoiesis material, which proposed the existence A way of humoral factors in feedback regulation of blood cell production. the first time in 30 years later was able to confirm this view, this factor was named as erythropoietin. Natural EPO is a glycoprotein containing sialic acid, the molecular weight of 34 000 by the 165 amino acids. who EPO gene is located in long arm of chromosome No. 7 District 11 ~ 12 by 4 introns (1 562 bp) and 5 exons (582 bp) form. by the synthesis of recombinant DNA technology recombinant human erythropoietin (rhEPO molecular weight of 30 400, its physical and chemical properties and biological activity of natural endogenous erythropoietin same. CNS are known to exist of brain-derived EPO, the molecular weight (33 kD than the serum EPO (35 kD is small, probably because it is smaller sialic acid-based, but the e